Wall Street brokerages expect that Cue Biopharma Inc (NASDAQ:CUE) will post $920,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Cue Biopharma’s earnings. The highest sales estimate is $1.02 million and the lowest is $810,000.00. Cue Biopharma posted sales of $1.06 million during the same quarter last year, which would suggest a negative year over year growth rate of 13.2%. The firm is expected to issue its next earnings results on Thursday, August 13th.
According to Zacks, analysts expect that Cue Biopharma will report full year sales of $8.99 million for the current year, with estimates ranging from $3.10 million to $17.40 million. For the next fiscal year, analysts forecast that the business will post sales of $14.01 million, with estimates ranging from $1.12 million to $27.30 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Cue Biopharma.
Cue Biopharma (NASDAQ:CUE) last posted its earnings results on Tuesday, May 19th. The company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.15). Cue Biopharma had a negative net margin of 959.08% and a negative return on equity of 103.99%.
NASDAQ:CUE opened at $18.91 on Thursday. Cue Biopharma has a fifty-two week low of $6.95 and a fifty-two week high of $31.69. The company has a 50 day moving average price of $23.20 and a 200 day moving average price of $20.43.
In other news, Director Aaron G.L. Fletcher bought 7,500 shares of Cue Biopharma stock in a transaction that occurred on Wednesday, June 24th. The shares were purchased at an average price of $24.88 per share, with a total value of $186,600.00. Following the completion of the acquisition, the director now directly owns 155,499 shares in the company, valued at $3,868,815.12. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.50% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of CUE. Fred Alger Management LLC acquired a new stake in Cue Biopharma in the first quarter valued at $57,000. Victory Capital Management Inc. raised its position in shares of Cue Biopharma by 13.8% during the 1st quarter. Victory Capital Management Inc. now owns 4,310 shares of the company’s stock worth $61,000 after acquiring an additional 522 shares in the last quarter. Meeder Asset Management Inc. lifted its stake in Cue Biopharma by 27,976.5% during the first quarter. Meeder Asset Management Inc. now owns 4,773 shares of the company’s stock worth $67,000 after purchasing an additional 4,756 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Cue Biopharma in the second quarter valued at approximately $80,000. Finally, Citigroup Inc. increased its stake in Cue Biopharma by 49.3% in the first quarter. Citigroup Inc. now owns 6,069 shares of the company’s stock valued at $86,000 after purchasing an additional 2,005 shares during the last quarter. 45.95% of the stock is currently owned by hedge funds and other institutional investors.
About Cue Biopharma
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
Featured Story: Basic Economics
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.